Phenotype 2 of deoxyribonuclease I may be used as a risk factor for gastric carcinoma.

Abstract

Human deoxyribonuclease I (DNase I) (EC3.1.21.1) is one of the candidate nucleases that acts in mammalian cells during apoptosis. Genetic polymorphism of DNase I has been classified into 15 phenotypes controlled by 5 autosomal codominant alleles. The purpose of this study was to determine whether DNase I polymorphism is closely related to the incidence of gastric carcinoma. The phenotype distribution was examined using urine samples obtained from unrelated Japanese patients with gastric carcinoma (n = 97) and benign gastric diseases (n = 76). Phenotyping was performed using isoelectric focusing electrophoresis in thin polyacrylamide gel and immunoblotting with an antihuman DNase I antibody. A close statistical association was found between patients with gastric carcinoma and a high frequency of DNase I phenotype 2. However, there was no significant difference in the phenotype distribution between the group of patients with benign gastric diseases and the controls. The findings of the current study suggest that DNase I phenotype 2 may be a marker for gastric carcinoma. Therefore, compared with other phenotypes, DNase I phenotype 2 may have potential for identifying patients who are at risk of harboring or developing gastric carcinoma.